Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually
relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a
cell surface receptor that expressed primarily by malignant and normal plasma cells. This is
a single-arm that includes three arms, Selinexor(ATG-010) in Combination with Immunomodulator
(Thalidomide/ Pomalidomide/ Lenalidomide）and Dexamethasone to Treat Relapsed/Refractory
Multiple Myeloma Patients. To evaluate efficacy and safety of Selinexor in combination with
Immunomodulator and Dexamethasone in RRMM patients received at least one prior lines of
therapy.